Richard Epstein on Regulation

Episode Summary

Executive Summary: Richard Epstein argues that the U.S. economy is being slowed less by the business cycle than by a deep, cumulative surge in regulation, litigation, and compliance costs. He sees health care, financial reform, FDA policy, and tort law as increasingly anti-innovation, discouraging investment, entrepreneurship, and growth while shifting resources from production to oversight.

Main Topics: Broad economic stagnation and weak private-sector growth (Priority: 5/5): Epstein says the recovery has stalled, labor-force growth is weak, unemployment remains elevated, and capital values are not rising in line with normal growth expectations. Regulatory accumulation and compliance costs (Priority: 5/5): He argues that the U.S. has entered a new era of dense, detailed regulation where marginal costs now outweigh benefits, producing a 'death of a thousand cuts' to business activity. Health care and financial reform as examples of overreach (Priority: 5/5): He criticizes the Affordable Care Act and Dodd-Frank as sprawling statutes that generate confusing mandates, hidden costs, and incentives that undermine productive activity. FDA, drug approval, and tort liability (Priority: 5/5): Epstein contends the FDA is too cautious, slowing drug availability, while tort suits and warning-label litigation create excessive risk and raise the cost of innovation. Market distortions from government intervention (Priority: 4/5): He argues that government-backed entities and interventions, such as Fannie Mae/Freddie Mac and mark-to-market rules, worsened the financial crisis and distorted rational market behavior. Political economy and bundling of legislation (Priority: 4/5): He says Congress bundles unrelated items into major bills, allowing favored provisions to ride along with broad reforms and making harmful regulation harder to unwind.

Key Arguments: The recovery is weak because the private sector is not creating enough jobs or capital investment, while government employment and compliance activity grow. Modern regulation has become far more detailed and comprehensive than earlier waves, making each new layer more costly and less beneficial. Health care and financial reform impose unclear mandates that create uncertainty, reduce ambition, and discourage mergers, research, and entrepreneurship. Sarbanes-Oxley and similar rules make it harder for small firms to go public, pushing innovation into large incumbents and reducing dynamism. The FDA is constrained by political pressure to avoid approving risky drugs, which delays beneficial treatments and encourages off-label workarounds. Tort litigation often targets warning labels rather than true misconduct, forcing firms to over-warn, raising costs, and reducing drug usage even when therapies are beneficial. Government guarantees and subsidies, especially in housing finance, distorted incentives and helped fuel reckless lending and securities creation. Bundled legislation lets lawmakers pass unrelated and potentially harmful provisions through omnibus bills with little scrutiny.

Data Points: U.S. stock market level: around 10,000 - Epstein uses this to argue capital values have stalled far below prior highs. Prior stock market high: a little above 14,000 - Referenced as the pre-crisis comparison point. Health care bill length: over 2,000, close to 3,000 pages - Used to illustrate the scale and complexity of modern regulation. Regulatory mandates in health care bill: probably 300 or 400 - Epstein estimates the number of regulations embedded in the bill. Unemployment benefits duration: 99 weeks - He argues extended benefits changed the composition and duration of unemployment. Federal tax/revenue share: moving up by 3 or 4 percent - He says the fiscal burden has risen materially, from roughly 20–21% to 24–25%. Revenue share before/after: about 20–21% to 24–25% - Illustrates the scale of government absorption of income. Number of listed companies: about 2,000 - Used in his Sarbanes-Oxley example about excessive prophylactic regulation. Problem firms in Sarbanes-Oxley example: 4 - He contrasts a few fraud cases with the burden imposed on all listed firms. Foreign high-level immigrants: quotas are not filled - He claims regulatory and policy burdens discourage top talent from coming to the U.S. FDA use of some cancer drugs: 80–90% off-label - Cited as evidence that approved drugs are widely used outside original FDA labels. Drug development cost: a billion-plus dollars - He says approval costs have risen sharply due to longer and more expensive trials. FDA warning regime effect: thousandfold increase in marketing cost - His estimate of tort/warning-related cost inflation relative to actual side effects. Medicare solvency extension claim: 11 or 12 years - He cites the trustees report as understating future fiscal problems.

Pivotal Quotes: "This is a death of a thousand cuts." — Richard Epstein: He summarizes the cumulative effect of regulation across industries. "Nobody is crazy enough to regulate to the point where people are out on the streets starving in droves, but they all think that somehow or other the incremental effect of their little old regulation ... is not going to have that much of an effect." — Richard Epstein: He explains how small regulatory actions can still produce large aggregate harm. "The only thing I start to do is to get more pessimistic still." — Richard Epstein: He concludes that macroeconomic policy ignores deeper regulatory dysfunction.

Implications: Listeners should expect slower growth, fewer startups, more compliance hiring, and greater legal uncertainty unless regulation, tort rules, and legislative bundling are reined in. Epstein’s view implies that recovery depends more on institutional simplification than stimulus.